Breaking News

Dendreon Restructures

Will lay off 600 in quest for profitability

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Dendreon has announced a strategic restructuring plan designed to accelerate the company’s path to profitability and future growth. The company will close its Morris Plains, NJ manufacturing facility, restructure administrative functions and strengthening commercial functions. The company expects to reduce costs by approximately $150 million annually with these moves, including a reduction in headcount of more than 600 full-time and contractor positions over the next 12 months. Full implementat...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters